Arterial Thrombosis – Pipeline Review, 2019

Arterial thrombosis is a blood clot developed in an artery. Arterial thrombosis can cause heart attack, stroke, transient ischaemic attack (TIA), critical limb ischemia and other complications in the human body. Arterial thrombosis can also be caused due to atrial fibrillation or antiphospholipid syndrome. One of the major cause of arterial thrombosis is attributed to the damaged artery due to a condition called atherosclerosis.

Current treatment for arterial thrombosis includes medication and surgery. The medications prescribed include anticoagulants such as heparin, warfarin, and others. The surgeries performed are coronary angioplasty, coronary artery bypass graft (CABG), carotid endarterectomy and others. In 2018, Portola Pharmaceuticals, Inc., received FDA approval for Andexanet alfa, an antidote for the rivaroxaban and apixaban, given at the time-reversal of anticoagulation due to uncontrolled bleeding.

Research Institutes and pharmaceutical companies are focusing on studying and developing new methods for the treatment of arterial thrombosis. For instance;

GP1, which is being studied by the Asan Foundation, is currently in phase-1 clinical trials for the study of safety, pharmacokinetics, biodistribution, and diagnostic performance of GP1 PET in thromboembolism.

Currently, more than 50% of the pipeline candidates for arterial thrombosis are in phase 3 and phase 4 stage. Majority of the studies have been sponsored by research institutes.

Report Description

The report on ‘Arterial Thrombosis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for arterial thrombosis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Arterial Thrombosis.

The report on ‘Arterial Thrombosis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for arterial thrombosis
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for arterial thrombosis
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary